WO2000034331A3 - Analogues of glp-1 - Google Patents

Analogues of glp-1 Download PDF

Info

Publication number
WO2000034331A3
WO2000034331A3 PCT/EP1999/009660 EP9909660W WO0034331A3 WO 2000034331 A3 WO2000034331 A3 WO 2000034331A3 EP 9909660 W EP9909660 W EP 9909660W WO 0034331 A3 WO0034331 A3 WO 0034331A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogues
glp
peptide
glucagon
pharmaceutically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/009660
Other languages
French (fr)
Other versions
WO2000034331A2 (en
Inventor
Zheng Xin Dong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26808753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2000034331(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP99963437A priority Critical patent/EP1137667B1/en
Priority to AT99963437T priority patent/ATE282635T1/en
Priority to HK01107772.8A priority patent/HK1037196B/en
Priority to NZ511931A priority patent/NZ511931A/en
Priority to CA2353574A priority patent/CA2353574C/en
Priority to KR10-2004-7006354A priority patent/KR100511855B1/en
Priority to HU0104574A priority patent/HUP0104574A3/en
Priority to US09/857,636 priority patent/US6903186B1/en
Priority to JP2000586773A priority patent/JP3702181B2/en
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to PL349468A priority patent/PL202367B1/en
Priority to SG200303507A priority patent/SG125915A1/en
Priority to IL14334699A priority patent/IL143346A0/en
Priority to DE69922043T priority patent/DE69922043T2/en
Priority to PL99362031A priority patent/PL189664B1/en
Priority to BR9915961-9A priority patent/BR9915961A/en
Priority to AU19736/00A priority patent/AU762012B2/en
Publication of WO2000034331A2 publication Critical patent/WO2000034331A2/en
Publication of WO2000034331A3 publication Critical patent/WO2000034331A3/en
Priority to NO20012786A priority patent/NO319128B1/en
Anticipated expiration legal-status Critical
Priority to NO20032093A priority patent/NO20032093D0/en
Priority to US10/629,261 priority patent/US7268213B2/en
Priority to US11/145,782 priority patent/US7235628B2/en
Priority to US11/781,096 priority patent/US8138305B2/en
Priority to US11/929,013 priority patent/US7977455B2/en
Priority to IL187907A priority patent/IL187907A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)

Abstract

The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.
PCT/EP1999/009660 1998-12-07 1999-12-07 Analogues of glp-1 Ceased WO2000034331A2 (en)

Priority Applications (23)

Application Number Priority Date Filing Date Title
AU19736/00A AU762012B2 (en) 1998-12-07 1999-12-07 Analogues of GLP-1
IL14334699A IL143346A0 (en) 1998-12-07 1999-12-07 Analogues of glp-1
HK01107772.8A HK1037196B (en) 1998-12-07 1999-12-07 Analogues of glp-1
NZ511931A NZ511931A (en) 1998-12-07 1999-12-07 Analogues of glucagon like peptide-1
PL99362031A PL189664B1 (en) 1998-12-07 1999-12-07 Analogues of glp-1
KR10-2004-7006354A KR100511855B1 (en) 1998-12-07 1999-12-07 Analogues of glp-1
HU0104574A HUP0104574A3 (en) 1998-12-07 1999-12-07 Analogues of glp-1, pharmaceutical compositions comprising thereof and their use
US09/857,636 US6903186B1 (en) 1998-12-07 1999-12-07 Analogues of GLP-1
JP2000586773A JP3702181B2 (en) 1998-12-07 1999-12-07 Analogs of GLP-1
AT99963437T ATE282635T1 (en) 1998-12-07 1999-12-07 GLP-1 ANALOGUE
PL349468A PL202367B1 (en) 1998-12-07 1999-12-07 Analogues of glp-1
SG200303507A SG125915A1 (en) 1998-12-07 1999-12-07 Analogues of glp-1
DE69922043T DE69922043T2 (en) 1998-12-07 1999-12-07 GLP-1 ANALOG
EP99963437A EP1137667B1 (en) 1998-12-07 1999-12-07 Analogues of glp-1
CA2353574A CA2353574C (en) 1998-12-07 1999-12-07 Analogues of glp-1
BR9915961-9A BR9915961A (en) 1998-12-07 1999-12-07 Glp-1 analogs
NO20012786A NO319128B1 (en) 1998-12-07 2001-06-06 Analogs of GLP-1, their use and pharmaceutical compositions.
NO20032093A NO20032093D0 (en) 1998-12-07 2003-05-09 Analogs of GLP-1
US10/629,261 US7268213B2 (en) 1998-12-07 2003-07-28 Analogues of GLP-1
US11/145,782 US7235628B2 (en) 1998-12-07 2005-06-06 Analogues of GLP-1
US11/781,096 US8138305B2 (en) 1998-12-07 2007-07-20 Analogues of GLP-1
US11/929,013 US7977455B2 (en) 1998-12-07 2007-10-30 Analogues of GLP-1
IL187907A IL187907A0 (en) 1998-12-07 2007-12-05 Analogues of glp-1 and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US20660198A 1998-12-07 1998-12-07
US11125598P 1998-12-07 1998-12-07
US60/111,255 1998-12-07
US09/206,601 1998-12-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US20660198A Continuation-In-Part 1998-12-07 1998-12-07

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US09857636 A-371-Of-International 1999-12-07
US09/857,636 A-371-Of-International US6903186B1 (en) 1998-12-07 1999-12-07 Analogues of GLP-1
US10/629,261 Division US7268213B2 (en) 1998-12-07 2003-07-28 Analogues of GLP-1
US10/629,261 Continuation-In-Part US7268213B2 (en) 1998-12-07 2003-07-28 Analogues of GLP-1
US11/145,782 Continuation US7235628B2 (en) 1998-12-07 2005-06-06 Analogues of GLP-1

Publications (2)

Publication Number Publication Date
WO2000034331A2 WO2000034331A2 (en) 2000-06-15
WO2000034331A3 true WO2000034331A3 (en) 2000-11-16

Family

ID=26808753

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/009660 Ceased WO2000034331A2 (en) 1998-12-07 1999-12-07 Analogues of glp-1

Country Status (22)

Country Link
US (5) US6903186B1 (en)
EP (2) EP1137667B1 (en)
JP (5) JP3702181B2 (en)
KR (3) KR20050037004A (en)
CN (2) CN1495198A (en)
AT (1) ATE282635T1 (en)
AU (1) AU762012B2 (en)
BR (1) BR9915961A (en)
CA (1) CA2353574C (en)
CZ (6) CZ295889B6 (en)
DE (1) DE69922043T2 (en)
ES (1) ES2230912T3 (en)
HU (1) HUP0104574A3 (en)
IL (2) IL143346A0 (en)
NO (2) NO319128B1 (en)
NZ (2) NZ511931A (en)
PL (1) PL202367B1 (en)
PT (1) PT1137667E (en)
RU (2) RU2288232C9 (en)
SG (1) SG125915A1 (en)
TW (6) TWI327069B (en)
WO (1) WO2000034331A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
PL208751B1 (en) 1998-12-07 2011-06-30 Sod Conseils Rech Applic GLP-1 analogues, compositions comprising thereof and the use thereof
CN1454214A (en) * 2000-08-02 2003-11-05 赛莱技术公司 Modified Biopeptides with Enhanced Efficacy
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
PT1326630E (en) 2000-09-18 2008-09-02 Sanos Bioscience As Use of glp-2 peptides
WO2002043709A1 (en) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Method for producing preparation containing bioactive substance
GB0100196D0 (en) * 2001-01-04 2001-02-14 Anmat Technology Ltd Peptides
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
GEP20063908B (en) * 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7332819B2 (en) * 2002-01-09 2008-02-19 Micron Technology, Inc. Stacked die in die BGA package
EP1543030A2 (en) * 2002-09-25 2005-06-22 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
WO2004037859A1 (en) * 2002-10-11 2004-05-06 Sanwa Kagaku Kenkyusho Co., Ltd. Glp-1 derivatives and transmicosal absorption preparations thereof
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
EP2067483A1 (en) * 2003-02-19 2009-06-10 Ipsen Pharma Analogues of GLP-1
JP4543236B2 (en) * 2003-03-28 2010-09-15 独立行政法人農業生物資源研究所 Method for producing plant storage organ with high production of recombinant protein and novel recombinant protein
DE10314610A1 (en) 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh New diphenylazetidinone with improved physiological properties, process for its preparation, medicaments containing these compounds and its use
ES2375056T3 (en) 2003-06-03 2012-02-24 Novo Nordisk A/S PEPT� COMPOSITIONS STABILIZED PHARMACEUTICAL DICAS
KR101308912B1 (en) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 Stabilized pharmaceutical peptide compositions
US7094800B2 (en) 2003-07-25 2006-08-22 Sanofi-Aventis Deutschland Gmbh Cyanopyrrolidides, process for their preparation and their use as medicaments
US7094794B2 (en) 2003-07-28 2006-08-22 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
DE10335092B3 (en) 2003-08-01 2005-02-03 Aventis Pharma Deutschland Gmbh Substituted benzoylureido-o-benzoylamides, process for their preparation and their use
JP2007514752A (en) * 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス GLP-1 pharmaceutical composition
EP1711523B1 (en) * 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
JP2007537141A (en) 2003-12-18 2007-12-20 ノボ　ノルディスク　アクティーゼルスカブ Novel GLP-1 compound
EP1709071A4 (en) * 2004-01-08 2007-05-30 Theratechnologies Inc PEPTIDE ANALOGUES 1 LIKE LONG-ACTING GLUCAGON-LIKE
TW200611704A (en) * 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
CN101010339B (en) * 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions
DE102004043153B4 (en) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin
JP2008515856A (en) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブ Delayed GLP-1 compound
JP5107713B2 (en) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス Delayed exendin-4 compound
JP5185624B2 (en) * 2004-12-02 2013-04-17 ドマンティス リミテッド Bispecific antibodies targeting serum albumin and GLP-1 or PYY
WO2006074051A2 (en) 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RESTORING β-CELL MASS AND FUNCTION
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
ES2484796T3 (en) 2005-03-18 2014-08-12 Novo Nordisk A/S Extended GLP-1 Compounds
US20070004616A1 (en) * 2005-06-30 2007-01-04 Roland Cherif-Cheikh GLP-1 pharmaceutical compositions
MX2008001468A (en) * 2005-06-30 2008-04-07 Sod Conseils Rech Applic Glp-1 pharmaceutical compositions.
CA2913805A1 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2007804B1 (en) 2006-04-20 2014-06-18 Amgen, Inc Glp-1 compounds
EP2020990B1 (en) 2006-05-30 2010-09-22 Intarcia Therapeutics, Inc Two-piece, internal-channel osmotic delivery system flow modulator
MX2008015935A (en) * 2006-06-23 2009-01-13 Hoffmann La Roche Insulinotropic peptide synthesis.
GB0612669D0 (en) * 2006-06-27 2006-08-09 Univ Leeds Biomarkers for preeclampsia
JP2010500300A (en) 2006-08-08 2010-01-07 サノフィ−アベンティス Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for their preparation, agents containing these compounds, and uses thereof
PL2359808T3 (en) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotic delivery systems and piston assemblies
MEP8509A (en) 2006-09-07 2011-12-20 Combination treatment for diabetes mellitus
RU2445972C2 (en) * 2006-12-29 2012-03-27 Ипсен Фарма С.А.С. Pharmaceutical compositions glp-1
CN101668535B (en) * 2006-12-29 2017-07-28 益普生制药股份有限公司 The pharmaceutical compositions of GLP 1
DE102007005045B4 (en) 2007-01-26 2008-12-18 Sanofi-Aventis Phenothiazine derivatives, process for their preparation and their use as medicines
NZ578948A (en) 2007-02-15 2012-03-30 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2025674A1 (en) 2007-08-15 2009-02-18 sanofi-aventis Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs
EP2190872B1 (en) 2007-09-05 2018-03-14 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100256056A1 (en) * 2007-09-07 2010-10-07 Zheng Xin Dong Analogues of exendin-4 and exendin-3
JP5473925B2 (en) 2007-10-27 2014-04-16 コーデン ファーマ コロラド インコーポレイテッド Synthesis of insulinotropic peptides using combined solid-phase and solution-phase techniques
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
DE102007054497B3 (en) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Novel crystalline diphenylazetidinone hydrates and process for their preparation
CA2707132A1 (en) * 2007-12-11 2009-06-18 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
ES2558842T3 (en) * 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Mixed agonists based on GIP for the treatment of metabolic disorders and obesity
CN105727261A (en) 2008-06-27 2016-07-06 杜克大学 Therapeutic agents comprising elastic peptides
WO2010015668A1 (en) 2008-08-06 2010-02-11 Novo Nordisk A/S Conjugated proteins with prolonged in vivo efficacy
KR20130133103A (en) * 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 Analogues of glucose-dependent insulinotropic polypeptide (gip) modified at n-terminal
CA2733005C (en) * 2008-08-07 2016-09-27 Ipsen Pharma S.A.S. Truncated analogues of glucose-dependent insulinotropic polypeptide
ES2574835T3 (en) * 2008-08-07 2016-06-22 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogs
CA2732949C (en) * 2008-08-07 2016-12-20 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
TW201012829A (en) * 2008-09-22 2010-04-01 Ipsen Mfg Ireland Ltd Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
AU2008365557A1 (en) 2008-12-15 2011-07-21 Zealand Pharma A/S Glucagon analogues
MA32970B1 (en) 2008-12-15 2012-01-02 Zealand Pharma As Isotope glucagon
ES2502218T3 (en) 2008-12-15 2014-10-03 Zealand Pharma A/S Glucagon analogues
US8642540B2 (en) 2008-12-15 2014-02-04 Zealand Pharma A/S Glucagon analogues
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp AMID-BASED PEPTIDE PRODRUGS OF THE GLUCAGON SUPERFAMILY
US20100183876A1 (en) * 2008-12-23 2010-07-22 Hell Andre Process for the Preparation of a Peptide Powder Form
WO2010072386A2 (en) 2008-12-23 2010-07-01 Roche Diagnostics Gmbh Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
JP5816097B2 (en) 2009-01-22 2015-11-18 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Stable growth hormone compound
EP2216042A1 (en) 2009-02-09 2010-08-11 Ipsen Pharma S.A.S. GLP-1 analogues pharmaceutical compositions
WO2010125079A2 (en) * 2009-05-01 2010-11-04 F. Hoffmann-La Roche Ag Insulinotropic peptide synthesis using solid and solution phase combination techniques
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
JP6054742B2 (en) 2009-07-13 2016-12-27 ジーランド ファーマ アクティーゼルスカブ Acylated glucagon analogues
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
SG178880A1 (en) 2009-08-26 2012-04-27 Sanofi Sa Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
WO2011048614A2 (en) 2009-10-22 2011-04-28 Cadila Healthcare Limited Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
PL2525834T3 (en) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
RU2012134974A (en) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг STABILIZED GROWTH HORMONE COMPOUND
KR20120123443A (en) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon antagonist - gip agonist conjugates and composition for the treatment of metabolic disorders and obesity
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
DE102010015123A1 (en) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh New benzylamidic diphenylazetidinone compounds, useful for treating lipid disorders, hyperlipidemia, atherosclerotic manifestations or insulin resistance, and for reducing serum cholesterol levels
PH12012502018A1 (en) 2010-04-30 2018-03-21 Sanwa Kagaku Kenkyusho Co Peptide for improving biostability of bioactive substance, and bioactive substance having improved biostability
EP2582709B1 (en) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US20110313131A1 (en) 2010-06-21 2011-12-22 Christelle Carl Reversed phase hplc purification of a glp-1 analogue
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
AR081975A1 (en) 2010-06-23 2012-10-31 Zealand Pharma As GLUCAGON ANALOGS
CA2802897A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MX377589B (en) 2010-12-16 2025-03-10 Novo Nordisk As Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
NZ612297A (en) 2010-12-22 2015-10-30 Univ Indiana Res & Tech Corp Glucagon analogs exhibiting gip receptor activity
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2683698B1 (en) 2011-03-08 2017-10-04 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683703B1 (en) 2011-03-08 2015-05-27 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2683704B1 (en) 2011-03-08 2014-12-17 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2766349B1 (en) 2011-03-08 2016-06-01 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
AU2012241894B2 (en) 2011-04-12 2015-12-03 Novo Nordisk A/S Double-acylated GLP-1 derivatives
CN103857408B (en) 2011-06-22 2017-04-12 印第安那大学科技研究公司 Glucagon/glp-1 receptor co-agonists
JP6184404B2 (en) 2011-06-22 2017-08-23 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション Glucagon / GLP-1 receptor co-agonist
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2715308T3 (en) 2012-03-22 2019-06-03 Novo Nordisk As Compositions comprising a supply agent and its preparation
KR102072202B1 (en) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Compositions of glp-1 peptides and preparation thereof
CA2872314C (en) 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
EP2851429B1 (en) 2012-05-18 2019-07-24 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
KR101848303B1 (en) 2012-07-10 2018-04-13 삼성전자주식회사 Method for controlling power trasnmitting of wireless power transmitter and the wireless power transmitter thereof
NZ704043A (en) 2012-07-23 2017-07-28 Zealand Pharma As Glucagon analogues
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analog
CN105142621A (en) 2012-10-24 2015-12-09 国家健康科学研究所 TPL2 kinase inhibitors for preventing or treating diabetes and promoting β-cell survival
CN104936610A (en) 2012-11-13 2015-09-23 益普生制药股份有限公司 Purification method of GLP-1 analog
WO2014077801A1 (en) 2012-11-13 2014-05-22 Ipsen Pharma S.A.S. Purification process for preparing highly pure taspoglutide
ES2841123T3 (en) 2013-04-05 2021-07-07 Formulacion Del Compuesto De La Hormona De Crecimiento Growth hormone compound formulation
RS58039B1 (en) 2013-05-02 2019-02-28 Novo Nordisk As Oral dosing of glp-1 compounds
US9738697B2 (en) 2013-06-23 2017-08-22 Wisconsin Alumni Research Foundation Alpha/beta-polypeptide analogs of glucagon-like peptide-1
CN103536907B (en) * 2013-07-18 2015-10-21 上海交通大学医学院附属瑞金医院 Application of liraglutide in the treatment of osteoporosis
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
AR098065A1 (en) 2013-10-17 2016-04-27 Zealand Pharma As GLUCAGON ANALOGS ACCILATED
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
CA2929459C (en) 2013-11-06 2022-05-03 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CA2933405A1 (en) * 2013-12-13 2015-06-18 Medimmune Limited Protease-resistant peptides
WO2015155151A1 (en) 2014-04-07 2015-10-15 Novo Nordisk A/S Double-acylated glp-1 compounds
WO2016034186A1 (en) 2014-09-05 2016-03-10 University Of Copenhagen Gip peptide analogues
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
PL3283507T3 (en) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylated glucagon analogue
ES2968262T3 (en) 2015-06-03 2024-05-08 I2O Therapeutics Inc Implant placement systems
CN106554409B (en) * 2015-09-30 2020-04-07 天津药物研究院有限公司 Long-acting glucagon-like peptide-1 analogue and application thereof
KR20240037175A (en) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 Glucagon-receptor selective polypeptides and methods of use thereof
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US11572399B2 (en) 2017-05-31 2023-02-07 University Of Copenhagen Long-acting GIP peptide analogues
AR114353A1 (en) 2018-02-02 2020-08-26 Novo Nordisk As SOLID COMPOSITIONS INCLUDING A GLP-1 AGONIST AND A SALT OF CAPRYLIC N- (8- (2-HYDROXIBENZOYL) AMINO)
MX2020009950A (en) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Modulators of g-protein coupled receptors.
SMT202200352T1 (en) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Novel glp-1 analogues
WO2019200594A1 (en) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Acylated glp-1 derivative
BR112021002207A2 (en) 2018-08-10 2021-05-04 Diapin Therapeutics, Llc tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
AU2019357621B2 (en) 2018-10-11 2025-04-03 Intarcia Therapeutics, Inc. Human amylin analog polypeptides and methods of use
CN109400695B (en) 2018-10-31 2020-06-30 中南大学湘雅医院 A kind of polypeptide modification method and application
US12187773B2 (en) 2018-12-03 2025-01-07 Antag Therapeutics Aps Modified GIP peptide analogues
AU2020418207A1 (en) 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
EP4281039A2 (en) 2021-01-25 2023-11-29 Mylan Ireland Limited Pharmaceutical glp peptide compositions and methods of preparation thereof
KR20240007251A (en) 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. Modulator of G-protein coupled receptors
CN114874314B (en) * 2021-12-28 2022-11-11 北京惠之衡生物科技有限公司 Recombinant engineering bacterium for highly expressing GLP-1 analogue and construction method thereof
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
KR102743491B1 (en) 2023-08-01 2024-12-17 (주)인벤티지랩 Microparticles containing semaglutide or pharmaceutically acceptable and method for producing the same
CN119569847A (en) * 2024-12-03 2025-03-07 中国科学院上海有机化学研究所 GLP-1 variants and their applications

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011457A1 (en) * 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO1998019698A1 (en) * 1996-11-05 1998-05-14 Eli Lilly And Company Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1539498A (en) 1925-05-26 And fifteen
JP2583257B2 (en) 1986-05-05 1997-02-19 ザ・ジェネラル・ホスピタル・コーポレーション Insulin tropism
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
BR9306551A (en) * 1992-06-15 1998-09-15 Pfizer Glucagon and insulinotropin peptide derivatives
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
CN1099416A (en) * 1993-08-21 1995-03-01 孙玉昆 Process for gene engineering production of IL 28-GLP-I
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
WO1997029180A1 (en) 1996-02-06 1997-08-14 Eli Lilly And Company Diabetes therapy
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US6458924B2 (en) * 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998032867A1 (en) * 1997-01-24 1998-07-30 Novo Nordisk A/S Synthetic leader peptide sequences
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
JP2002508162A (en) 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ GLP-1 derivative with shortened N-terminus
FR2777283B1 (en) * 1998-04-10 2000-11-24 Adir NOVEL GLUCAGON-PEPTIDE- 1 (7-37) ANALOGUE PEPTIDE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
US6720407B1 (en) * 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
PL208751B1 (en) 1998-12-07 2011-06-30 Sod Conseils Rech Applic GLP-1 analogues, compositions comprising thereof and the use thereof
EP1137667B1 (en) * 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
EP1239871A1 (en) 1999-11-12 2002-09-18 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
CN114612953B (en) 2020-12-09 2025-09-26 佳能株式会社 Object recognition model training method and device

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011457A1 (en) * 1990-01-24 1991-08-08 Buckley Douglas I Glp-1 analogs useful for diabetes treatment
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO1998019698A1 (en) * 1996-11-05 1998-05-14 Eli Lilly And Company Use of glp-1 analogs and derivatives administered peripherally in regulation of obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PARKER J C ET AL: "STRUCTURE-FUNCTION ANALYSIS OF A SERIES OF GLUCAGON-LIKE PEPTIDE-1 ANALOGS", JOURNAL OF PEPTIDE RESEARCH,DK,MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, vol. 52, no. 5, 1 November 1998 (1998-11-01), pages 398 - 409, XP000788444, ISSN: 1397-002X *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Also Published As

Publication number Publication date
RU2003112447A (en) 2005-02-20
US20080108566A1 (en) 2008-05-08
CN1329620A (en) 2002-01-02
US8138305B2 (en) 2012-03-20
KR20010080713A (en) 2001-08-22
AU1973600A (en) 2000-06-26
NO20032093D0 (en) 2003-05-09
CN100540566C (en) 2009-09-16
NO20012786L (en) 2001-07-20
TW200626613A (en) 2006-08-01
NO319128B1 (en) 2005-06-20
PT1137667E (en) 2005-02-28
TW593338B (en) 2004-06-21
EP1137667A2 (en) 2001-10-04
EP1137667B1 (en) 2004-11-17
PL202367B1 (en) 2009-06-30
US7977455B2 (en) 2011-07-12
JP2004131473A (en) 2004-04-30
NO20032093L (en) 2001-07-20
NO20012786D0 (en) 2001-06-06
BR9915961A (en) 2001-08-21
HUP0104574A2 (en) 2002-04-29
US7268213B2 (en) 2007-09-11
TW200422300A (en) 2004-11-01
JP4386887B2 (en) 2009-12-16
TW201041590A (en) 2010-12-01
WO2000034331A2 (en) 2000-06-15
CZ295889B6 (en) 2005-11-16
JP3934092B2 (en) 2007-06-20
RU2214418C2 (en) 2003-10-20
US20090197802A1 (en) 2009-08-06
SG125915A1 (en) 2006-10-30
IL187907A0 (en) 2008-03-20
NZ527241A (en) 2004-12-24
KR20040053220A (en) 2004-06-23
TW200302229A (en) 2003-08-01
RU2288232C2 (en) 2006-11-27
JP4620444B2 (en) 2011-01-26
JP2002531578A (en) 2002-09-24
EP2322545A1 (en) 2011-05-18
US6903186B1 (en) 2005-06-07
CA2353574C (en) 2012-05-08
JP2006151988A (en) 2006-06-15
KR100452417B1 (en) 2004-10-12
KR100511855B1 (en) 2005-09-02
KR20050037004A (en) 2005-04-20
ES2230912T3 (en) 2005-05-01
TWI327069B (en) 2010-07-11
NZ511931A (en) 2004-01-30
HK1037196A1 (en) 2002-02-01
ATE282635T1 (en) 2004-12-15
US20040018981A1 (en) 2004-01-29
CZ295891B6 (en) 2005-11-16
PL349468A1 (en) 2002-07-29
HUP0104574A3 (en) 2002-09-30
CZ295044B6 (en) 2005-05-18
RU2288232C9 (en) 2007-04-20
CZ295768B6 (en) 2005-10-12
DE69922043D1 (en) 2004-12-23
CZ20011748A3 (en) 2002-02-13
DE69922043T2 (en) 2005-11-24
JP2005132845A (en) 2005-05-26
CA2353574A1 (en) 2000-06-15
TWI255271B (en) 2006-05-21
AU762012B2 (en) 2003-06-19
JP2008001710A (en) 2008-01-10
TW200803889A (en) 2008-01-16
TWI327150B (en) 2010-07-11
TWI352599B (en) 2011-11-21
JP3702181B2 (en) 2005-10-05
CN1495198A (en) 2004-05-12
IL143346A0 (en) 2002-04-21
CZ294029B6 (en) 2004-09-15
CZ295890B6 (en) 2005-11-16
US7235628B2 (en) 2007-06-26
US20050233969A1 (en) 2005-10-20

Similar Documents

Publication Publication Date Title
TWI262925B (en) GLP-1 analogues
SG125915A1 (en) Analogues of glp-1
WO2005058252A3 (en) Glp-1 pharmaceutical compositions
WO2004074315A3 (en) Analogues of glp-1
EA200300026A1 (en) GLUKAGONOPODODODNOGNY PEPTIDA-1 ANALOGUES
WO2003061362A3 (en) Methods and compositions for treating polycystic ovary syndrome
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
UA35636C2 (en) Polypeptide possessing lung surfactant activity and pharmaceutical composition for treating respiratory distress syndrome in mammals
CO5090908A1 (en) PROCEDURE FOR MANAGING INSULINOTROPIC PEPTIDES
PT883687E (en) RECEPTORS OF CHIMIOCINES C-C, CKR-5, CC, THEIR DERIVATIVES AND THEIR USES
AU2002213925A1 (en) Use of glp-1 and flp-2 peptides for treatment of bone disorders
EP2210900A3 (en) Analogues of GLP-1
EP1359159A3 (en) Analogues of GLP-1
WO2007005738A3 (en) Glp-1 pharmaceutical compositions
AU7028798A (en) Use of 2-methylthiazolidine-2,4-dicarboxylic acid as mucolytic agent
UA88862C2 (en) Glucagon-like peptide-1 analogs
Yoshida Treatment of Fly Ash from Incineration

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99814187.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PV2001-1748

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 19736/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 143346

Country of ref document: IL

Ref document number: 511931

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2353574

Country of ref document: CA

Ref document number: 2353574

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001/04478

Country of ref document: ZA

Ref document number: 200104478

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2000 586773

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/782/CHE

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/005762

Country of ref document: MX

Ref document number: 1020017007113

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1999963437

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020017007113

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1999963437

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09857636

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: PV2003-1289

Country of ref document: CZ

Ref document number: PV2001-1748

Country of ref document: CZ

Ref document number: PV2004-572

Country of ref document: CZ

Ref document number: PV2004-573

Country of ref document: CZ

Ref document number: PV2004-591

Country of ref document: CZ

Ref document number: PV2004-592

Country of ref document: CZ

REF Corresponds to

Ref document number: 10083312

Country of ref document: DE

Date of ref document: 20021024

WWE Wipo information: entry into national phase

Ref document number: PV2003-1289

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 19736/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2004-572

Country of ref document: CZ

Ref document number: PV2004-573

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PV2004-591

Country of ref document: CZ

Ref document number: PV2004-592

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1020017007113

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: PV2001-1748

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1999963437

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV2003-1289

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV2004-573

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: PV2004-572

Country of ref document: CZ

Ref document number: PV2004-592

Country of ref document: CZ

Ref document number: PV2004-591

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 187907

Country of ref document: IL